Fig. 4.

Cholesterol biosynthesis pathway is related to MHC-I expression and simvastatin-reduced azelastine or HRH1 knockdown-related MHC-I upregulation. A Demographics of microarray analysis of MIA PaCa-2 or KP-2 treated with Az (20 µM) or H₂O for 48 h (upper), and the Metascape analysis pathway-enriched upregulated genes (lower). B RT-PCR for cholesterol biosynthesis-related gene expression in MIA PaCa-2 or KP-2 treated with Az (20 µM) for 48 h or KP-2 shHRH1 (sh1), n ≥ 3 per group. C The correlation plot shows cholesterol biosynthesis-related genes between T cell exhaustion scores by GEPIA 2.0. D MSMO1 or DHCR7 protein expression in whole lysis of siDHCR7 or siMSMO1, or Az (20 µM) or combination. E MFI of HLA-ABC expression using FCM for Az (20 µM) or combination, n = 3 per group. F CANX and CALR protein expression in KP-2 treated by Az (20 µM) or combined with simvastatin (10 µM) for 48 h. G MFI of HLA-ABC and B2M using FCM for MIA PaCa-2 or KP-2 treated alone or in combination, n ≥ 3 per group. Error bars, mean ± SD (B, E, G); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. MHC-I, major histocompatibility complex class I; RT-PCR, quantitative reverse transcription polymerase chain reaction; MFI, median fluorescence intensity; FCM, Flow cytometry